Skip to content
StockMarketAgent
Direct answer
Intuitive Surgical maintains a dominant, near-monopoly position in soft-tissue robotic surgery. Its massive installed base of da Vinci systems creates a razor-and-blade model with high switching costs, generating robust recurring revenues from instruments and accessories. Strong free cash flow generation and high ROIC solidify its status as a premier quality compounder. Fair value range: low $176, high $337, with mid-point at $255.
Stock analysis

ISRG Intuitive Surgical Inc. fair value $255–$337

ISRG
By StockMarketAgent.AI team· supervised by
Analyzed: 2026-05-09Next update: 2026-08-09Methodology v2.4Archetype: Mature compounderNASDAQ · Health Care
View archive
Last price
$450.06
▼ -195.39 (-43.41%)
Fair value
$255
$255–$337
Rating
Sell
confidence 87/100
Upside
-43.4%
upside to fair value
Margin of Safety
$216.47
buy below · 15%
Market Cap
$159.4B
P/E fwd 38.2

§1 Executive summary

  • Premium quality compounder with a wide competitive moat.
  • Reverse DCF implies ~20% perpetual growth required at current $450 price.
  • Intrinsic valuation models anchor at $254.67, signaling a massive premium.
  • Sell recommendation driven by extreme valuation disconnect, not business quality.
Fair value
$255
Margin of safety
-76.7%
Confidence
87/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$450.06Price
FV $254.67
High $336.56

Intuitive Surgical maintains a dominant, near-monopoly position in soft-tissue robotic surgery. Its massive installed base of da Vinci systems creates a razor-and-blade model with high switching costs, generating robust recurring revenues from instruments and accessories. Strong free cash flow generation and high ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. solidify its status as a premier quality compounder.

  • Massive installed base of da
    Massive installed base of da Vinci systems
  • High switching costs for hospitals
    High switching costs for hospitals and surgeons
  • Cycle upside
    Post-pandemic procedure backlog clearance drives elevated system utilization and instrument consumption.

§2 Bear case

A severe hospital capexCapital expendituresCash spent on acquiring or upgrading property, plant, and equipment. Splits into maintenance capex (sustaining current capacity) and growth capex (expanding capacity). freeze combined with accelerated placements of competing systems like Medtronic's Hugo compresses margins and slows new system placements significantly.

Ways this thesis can break

Medtronic/J&J Capture 30% Market Share

· Low

Competitors successfully disrupt the monopoly, forcing severe pricing pressure on systems and instruments.

FV impact
Downside below $175
Trigger
2-3 Years

Severe Hospital Capex Freeze

· Medium

Macro-driven hospital budget cuts drastically slow new system placements and upgrade cycles globally.

FV impact
Downside to $190
Trigger
1-2 Years

New Modality Disruption

· Low

Emergence of non-robotic, highly effective minimally invasive alternatives permanently reduces TAM for da Vinci.

FV impact
Downside to $160
Trigger
5+ Years
Early-warning signals to monitor
MetricCurrentTrigger threshold
Decline in da Vinci procedure volume growth below 10%MonitorDeterioration versus the report thesis
Compression of gross margins below 60%MonitorDeterioration versus the report thesis
System placement growth turning negative YoYMonitorDeterioration versus the report thesis
Competitor system FDA approvals with superior clinical dataMonitorDeterioration versus the report thesis
Significant insider selling coupled with guidance cutsMonitorDeterioration versus the report thesis

§3 Financial history

Income statement — last six periods
Line itemT−0T−1T−2T−3CAGR
Period2022-12-312023-12-312024-12-312025-12-31Trend
Revenue$6.22B$7.12B$8.35B$10.06B+17.4%
Gross profit$4.20B$4.73B$5.63B$6.64B+16.5%
Operating income$1.58B$1.77B$2.35B$2.95B+23.1%
Net income
EPS (diluted)$3.65$5.03$6.42$7.87+29.2%
EBITDA$1.94B$2.22B$2.85B$3.62B+23.1%
R&D$879.0M$998.8M$1.15B$1.31B+14.3%
SG&A$1.74B$1.96B$2.14B$2.39B+11.1%

Quality scores

Piotroski F-score
7 / 9
0–9 quality composite
Altman Z-score
39.9
Bankruptcy risk (>3 safe)
OCF / Net income
1.06×
>1 indicates high earnings quality
Accounting quality gate
Pass
Sector-adjusted gate
ROIC
13.0%
Return on invested capital
§3

Numbers analysis

Individual subscribers — §4 onwards11 more sections

Read the full analysis — 11 more sections.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Full report for every covered ticker
24 months of rating archive
Watchlist briefings + rating-change alerts
PDF + DOCX export in any language
Start free trial
Cancel anytime.
FAQ

ISRG — frequently asked questions

  1. Based on our latest independent analysis, ISRG looks meaningfully overvalued. The current price is $450 versus a composite fair-value midpoint of $255 (range $176–$337), which implies roughly 43.4% downside to the midpoint.
Related coverage

Names readers of ISRG also follow

Same archetype: mature-compounder
Same sector: Health Care